Canada - English - Health Canada

sanis health inc - midodrine hydrochloride - tablet - 5mg - midodrine hydrochloride 5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva pharma uk ltd - midodrine hydrochloride - oral tablet - 2.5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva pharma uk ltd - midodrine hydrochloride - oral tablet - 5mg

Ireland - English - HPRA (Health Products Regulatory Authority)

originalis b.v. - midodrine hydrochloride - tablet - midodrine

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novugen pharma sdn. bhd. - midodrine hydrochloride -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novugen pharma sdn. bhd. - midodrine hydrochloride -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novugen pharma sdn. bhd. - midodrine hydrochloride -

Ireland - English - HPRA (Health Products Regulatory Authority)

nycomed uk limited - midodrine hydrochloride - tablets - 2.5 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

nycomed uk limited - midodrine hydrochloride - tablets - 5 milligram

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - midodrine hydrochloride 2.5mg - tablet - 2.5 mg - active: midodrine hydrochloride 2.5mg excipient: hydrated silica magnesium stearate microcrystalline cellulose purified talc starch - gutron is indicated to attenuate symptoms of chronic orthostatic hypotension due to automatic failure in patients with bradbury-eggleston or shy-drager syndromes and other medical disorders such as diabetes mellitus or parkinson's disease. because midodrine can cause marked elevation of supine blood pressure, it should only be used in patients whose lives are considerably impaired despite standard clinical care including non-pharmacologic treatment, plasma volume expansion and lifestyle alterations. the initiation of gutron therapy should be undertaken under close medical supervision in a controlled clinical setting.